In this trial, we will transfer fecal microbiota originating from either responding or nonresponding metastatic melanoma patients via FMT while continuing with immunotherapy (anti-PD-1), with the aim to revert ICI unresponsiveness of anti-PD-1 refractory advanced stage melanoma patients. The gene discussed is PDCD1; the disease is melanoma.